Skip to main content
RemeGen Co., Ltd. logo

RemeGen Co., Ltd. — Investor Relations & Filings

Ticker · 9995 ISIN · CNE1000048G6 LEI · 300300M9HCX4TFAD4I10 HKEX Manufacturing
Open in API
Filings indexed 1,624 across all filing types
Latest filing 2025-02-06 Board/Management Inform…
Country CN China
Listing HKEX 9995

About RemeGen Co., Ltd.

http://www.remegen.com

RemeGen Co., Ltd. is a biopharmaceutical company dedicated to the discovery, development, production, and commercialization of innovative biological drugs. The company focuses on creating first-in-class and best-in-class therapeutics to address significant unmet clinical needs, particularly in the critical therapeutic areas of autoimmune diseases, oncology, and ophthalmology. RemeGen utilizes proprietary technology platforms capable of discovering, screening, and developing new molecules and efficiently optimizing production processes. Its pipeline includes a series of innovative biologics, such as Telitacicept, and features 8 clinical pipelines, over 40 clinical trials, and more than 600 patent applications, demonstrating a strong commitment to R&D and innovation in biopharmaceuticals.

Recent filings

Filing Released Lang Actions
ANNOUNCEMENT ON THE RESIGNATION OF AN EXECUTIVE DIRECTOR
Board/Management Information Classification · 97% confidence The document is a formal announcement of the resignation of an executive director, detailing board composition changes and confirming the vacancy and replacement process. This matches the definition for Board/Management Information (MANG).
2025-02-06 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2025
Regulatory Filings Classification · 85% confidence The document is an HKEX FF301 Monthly Return for Equity Issuer covering movements in authorized and issued share capital, share options, convertibles and other arrangements. It is a required periodic regulatory filing under the Exchange Listing Rules (Chapter 19B) rather than an announcement of a specific corporate event or the report of an audit, earnings, or AGM materials. It does not fit specialized categories like Share Issue/Capital Change (SHA) since it is a routine monthly return rather than a one‐off capital issue announcement, nor does it match earnings, board changes, or proxy materials. Therefore it falls into the fallback “Regulatory Filings” category.
2025-02-06 English
Monthly Return of Equity Issuer on Movement in Securities for the month ended 31 January 2025
Regulatory Filings Classification · 85% confidence The document is a routine monthly return (Form FF301) submitted to the Hong Kong Exchanges and Clearing Limited, detailing movements in authorised share capital, issued shares, share options, warrants, convertibles, and other share-related confirmations. It does not present financial results (ER or IR), nor is it a full Annual or Interim Report (10-K/IR), nor an earnings call transcript, nor a presentation. It is not a notice of dividend, share issue announcement with new issuance or repurchase specifics, nor a management change or M&A announcement. It is a regulatory filing required under Chapter 19B of the HKEX Listing Rules for monthly securities movements, which does not fit any more specific category. Hence, it should be classified under the fallback category for miscellaneous regulatory announcements: Regulatory Filings (RNS).
2025-02-06 English
INSIDE INFORMATION-ESTIMATED 2024 ANNUAL RESULTS
Earnings Release Classification · 85% confidence The document is titled “INSIDE INFORMATION ESTIMATED 2024 ANNUAL RESULTS” and provides preliminary, unaudited key financial metrics (revenue, net loss, year‐on‐year changes, reasons for change) for the full 2024 year. It is an initial announcement of periodical (annual) financial results, not the full audited annual report. This matches the definition of an Earnings Release (Code: ER). FY 2024
2025-01-16 English
LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS
Governance Information Classification · 85% confidence The document is a formal listing of the company’s board members and their committee roles, including executive, non-executive, and independent non-executive directors, as well as the composition of four board committees. It does not announce specific changes (appointments or resignations), nor is it an AGM voting result, earnings release, or other financial report. Instead, it details the company’s governance structure and committee makeup, which aligns with the definition of a Governance Information (CGR) filing.
2025-01-10 English
POLL RESULTS OF THE 2025 FIRST EXTRAORDINARY GENERAL MEETING
Declaration of Voting Results & Voting Rights Announcements Classification · 90% confidence The document is an official announcement by RemeGen Co., Ltd. detailing the poll results of its 2025 first Extraordinary General Meeting (EGM), including the vote counts for the ordinary resolution and the subsequent change in board composition. This fits the definition of "Declaration of Voting Results & Voting Rights Announcements" (DVA), which covers official results from shareholder votes at any general meeting. There is no indication that this is a full report or financial filing, nor is it merely notifying publication of another report. Therefore, the correct classification is DVA.
2025-01-10 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.